Molecular regulation of lipotoxicity in the heart

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 1, 2005, Pages 101-107

  Yang, Qinglin ^a   Cheng, Lihong ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; LIPID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

APOPTOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; DRUG POTENCY; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART DISEASE; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 33645061259     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.032     Document Type: Review

References (39)

1. L.L. Listenberger J.E. Schaffer Mechanisms of lipoapoptosis: implications for human heart disease Trends Cardiovasc. Med. 12 2002 134-138
2. C. Christoffersen et. al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice Endocrinology 144 2003 3483-3490
3. Y.T. Zhou et. al. Lipotoxic heart disease in obese rats: Implications for human obesity Proc. Natl. Acad. Sci. USA 97 2000 1784-1789
4. B. Wittels J.F. Spann Jr. Defective lipid metabolism in the failing heart J. Clin. Invest. 47 1968 1787-1794
5. B.M. Massie et. al. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy Circulation 91 1995 1814-1823
6. S.P. Bishop R.A. Altschuld Increased glycolytic metabolism in cardiac hypertrophy and congestive failure Am. J. Physiol. 218 1970 153-159
7. S. Sharma et. al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart FASEB J. 18 2004 1692-1700
8. A. Alaud-din et. al. Assessment of cardiac function in patients who were morbidly obese Surgery 108 1990 809-818
9. A. Kamataki et. al. Remnant lipoprotein particles are taken up into myocardium through VLDL receptor - a possible mechanism for cardiac fatty acid metabolism Biochem. Biophys. Res. Commun. 293 2002 1007-1013
10. H.C. Chiu et. al. A novel mouse model of lipotoxic cardiomyopathy J. Clin. Invest. 107 2001 813-822
11. H.C. Chiu et. al. Transgenic expression of FATP1 in the heart causes lipotoxic cardiomyopathy Circ. Res. 96 2004 225-233
12. H. Yagyu et. al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy J. Clin. Invest. 111 2003 419-426
13. S.L. Coort et. al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats Diabetes 53 2004 1655-1663
14. D.E. Greenwalt et. al. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet J. Clin. Invest. 96 1995 1382-1388
15. J.F. Glatz et. al. Rat heart fatty acid-binding protein content is increased in experimental diabetes Biochem. Biophys. Res. Commun. 199 1994 639-646
16. M.N. Sack et. al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart Circulation 94 1996 2837-2842
17. S.S. Lee et. al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell. Biol. 15 1995 3012-3022
18. Y. Barak et. al. PPAR gamma is required for placental, cardiac, and adipose tissue development Mol. Cell 4 1999 585-595
19. J.M. Peters et. al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta) Mol. Cell Biol. 20 2000 5119-5128
20. Y. Barak et. al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer Proc. Natl. Acad. Sci. USA 99 2002 303-308
21. F. Djouadi et. al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice J. Clin. Invest. 102 1998 1083-1091
22. B.N. Finck et. al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus J. Clin. Invest. 109 2002 121-130
23. B.N. Finck et. al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content Proc. Natl. Acad. Sci. USA 100 2003 1226-1231
24. A.J. Gilde et. al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism Circ. Res. 92 2003 518-524
25. L. Cheng et. al. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes Biochem. Biophys. Res. Commun. 313 2004 277-286
26. S. Kersten et. al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting J. Clin. Invest. 103 1999 1489-1498
27. L. Cheng et. al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nat. Med. 10 2004 1245-1250
28. J. Boren et. al. Apo B100-containing lipoproteins are secreted by the heart J. Clin. Invest. 101 1998 1197-1202
29. L.B. Nielsen et. al. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: Evidence that the heart has the capacity to synthesize and secrete lipoproteins Circulation 98 1998 13-16
30. L.B. Nielsen et. al. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice J. Biol. Chem. 277 2002 27014-27020
31. J. Bjorkegren et. al. Lipoprotein secretion and triglyceride stores in the heart J. Biol. Chem. 276 2001 38511-38517
32. M. Yokoyama et. al. Apolipoprotein B production reduces lipotoxic cardiomyopathy: Studies in heart-specific lipoprotein lipase transgenic mouse J. Biol. Chem. 279 2004 4204-4211
33. M.Y. Wang R.H. Unger Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone Am. J. Physiol. Endocrinol. Metab. 288 2005 E216-E221
34. G.C. Sparagna et. al. Fatty acid-induced apoptosis in neonatal cardiomyocytes: Redox signaling Antioxid. Redox Signal. 3 2001 71-79
35. J.E. de Vries et. al. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes J. Lipid Res. 38 1997 1384-1394
36. D.B. Ostrander et. al. Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis J. Biol. Chem. 276 2001 38061-38067
37. R.K. Vikramadithyan et. al. Peroxisome proliferator activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy J. Pharmacol. Exp. Ther. 313 2005 586-593
38. I. Takada et. al. Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype Mol. Endocrinol. 14 2000 733-740
39. L.L. Atkinson et. al. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis J. Biol. Chem. 277 2002 29424-29430